Early detection of severe sepsis in the emergency room: Diagnostic value of plasma C-reactive protein, procalcitonin, and interleukin-6

Abstract Objectives: To determine the diagnostic values of plasma C-reactive protein (CRP), procalcitonin (PCT), and interleukin-6 (IL-6) using an electrochemiluminescence immunoassay (ECLIA) method (Roche Diagnostics GmbH, Mannheim, Germany) to identify severe sepsis in an emergency room (ER) setting. Methods: This was a single-centre prospective follow-up study of 539 consecutive adult patients admitted to the ER with suspected infection. Blood samples were taken concurrently with blood cultures at admission. Patients were divided into 5 groups on the basis of systemic inflammatory response syndrome (SIRS) criteria, documentation of bacterial infection, and organ dysfunction. Fifty-nine patients with no SIRS or bacterial infection, 68 patients with bacterial infection but no SIRS, 54 patients with SIRS but no bacterial infection, 309 patients with sepsis (SIRS and bacterial infection), and 49 patients with severe sepsis (sepsis and organ failure) were evaluated. Results: In a logistic regression model, the odds ratio (OR) for PCT was 1.58 (95% confidence interval (CI) 1.37–1.82, p < 0.0001), for IL-6 was 1.54 (95% CI 1.32–1.80, p < 0.0001), and for CRP was 1.33 (95% CI 1.01–1.75, p = 0.045). The area under the curve (AUC) was 0.77 (95% CI 0.71–0.84) for PCT, 0.72 (95% CI 0.64–0.80) for IL-6, and 0.60 (95% CI 0.51–0.69) for CRP. PCT emerged as the best marker for severe sepsis, but the difference in AUC was not significant between PCT and IL-6. In multivariate logistic regression analysis, after adjusting for confounders, PCT and IL-6 remained significant independent predictors of severe sepsis. Conclusions: PCT and IL-6 proved superior to CRP in detecting patients with severe sepsis. The findings thus support the use of either PCT or IL-6 as an early tool to diagnose severe sepsis. The automatic ECLIA method allows even night-shift measurements.

[1]  France Gauvin,et al.  Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  F. Tubach,et al.  Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial , 2010, The Lancet.

[3]  Anthony S McLean,et al.  Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. , 2007, The Lancet. Infectious diseases.

[4]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[5]  R. Bone Guidelines for the Use of Innovative Therapies in Sepsis , 1993 .

[6]  B. Bein,et al.  Procalcitonin to guide duration of antibiotic therapy in intensive care patients: a randomized prospective controlled trial , 2009, Critical care.

[7]  K. Byth,et al.  Procalcitonin: A Marker of Bacteraemia in SIRS , 2003, Anaesthesia and intensive care.

[8]  E. Ruokonen,et al.  Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study , 2007, Intensive Care Medicine.

[9]  J. V. D. van den Ouweland,et al.  Comparison of a new procalcitonin assay from roche with the established method on the brahms kryptor. , 2009, Clinical chemistry.

[10]  Jih-Chang Chen,et al.  Procalcitonin as a marker of bacterial infection in the emergency department: an observational study , 2003, Critical care.

[11]  S. Kushimoto,et al.  Multicenter prospective study of procalcitonin as an indicator of sepsis , 2005, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[12]  M. Levy,et al.  Surviving Sepsis Campaign: International guidelines for management of severe sepsis and septic shock: 2008 , 2007, Intensive Care Medicine.

[13]  J. Bertrand,et al.  Can emergency physicians identify a high mortality subgroup of patients with sepsis: role of procalcitonin , 2008, European journal of emergency medicine : official journal of the European Society for Emergency Medicine.

[14]  Corinne Alberti,et al.  Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. , 2003, American journal of respiratory and critical care medicine.

[15]  U. Sungurtekin,et al.  Usefulness of procalcitonin for diagnosis of sepsis in the intensive care unit , 2002, Critical care.

[16]  Richard Beale,et al.  The Surviving Sepsis Campaign: results of an international guideline-based performance improvement program targeting severe sepsis , 2010, Intensive Care Medicine.

[17]  Patrick Nicolas,et al.  Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: A systematic review and meta-analysis , 2006, Critical care medicine.

[18]  P. Póvoa,et al.  Is C-reactive protein a good prognostic marker in septic patients? , 2009, Intensive Care Medicine.

[19]  D. Pittet,et al.  The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. , 1995, JAMA.

[20]  J. Garnacho-Montero,et al.  Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis* , 2003, Critical care medicine.

[21]  H. Metzler,et al.  Procalcitonin's role in the sepsis cascade. Is procalcitonin a sepsis marker or mediator? , 2009, Minerva anestesiologica.

[22]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.